Grades, scores, and FDA catalyst signals for Neurology & CNS stocks tracked by BiotechSigns
| Ticker | Company | Score | Grade | Sector | Signals |
|---|---|---|---|---|---|
| AQUA | Aquestive Therapeutics | 93 | A | CNS | — |
Central nervous system drugs — targeting Alzheimer's disease, Parkinson's disease, ALS, depression, epilepsy, schizophrenia, and other neurological conditions — have notoriously high failure rates. The blood-brain barrier creates delivery challenges, biomarker development lags behind oncology, and placebo response rates in psychiatric trials complicate endpoint achievement. These factors make PDUFA dates in neurology especially high-risk and high-reward. Recent Alzheimer's approvals (Leqembi, Kisunla) have renewed investor interest and validated amyloid-targeting approaches. CNS companies often require multiple Phase 3 attempts, making capital efficiency a critical investor concern. Novel delivery mechanisms and biomarker-selected patient populations are the frontier of CNS development.